|Day Low/High||20.75 / 21.10|
|52 Wk Low/High||10.85 / 37.94|
The Dow, S&P 500 and Nasdaq all finish higher on Thursday.
Japanese, Hong Kong and European markets continue Wednesday's Wall Street rally.
We used to think of what's in the public's interest when it comes to securities.
The insurgent manager that helped engineer the Amazon-Whole Foods combination just offered up a window into his latest allocations, any of which could soon become campaigns. Both Jana Partners and Warren Buffett's Berkshire Hathaway Inc. reported new positions in Teva
Berkshire Hathaway purchased 18.9 million shares of the drugmaker, according to its 13F filing.
Warren Buffett continues to eat up Apple's stock. He also has bought a stake in struggling generics drug maker Teva.
This is the second generic Copaxone 40 mg/mL greenlighted by the U.S. Food and Drug Administration.
Stocks ended higher on Tuesday.
As lawsuits tied to the opioid crisis keep piling up, Purdue Pharma is discontinuing direct sales calls to doctors. Will other opioid makers follow suit?
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that QVAR ® RediHaler ™ (beclomethasone dipropionate HFA) Inhalation Aerosol is now commercially available to patients in both 40 mcg and...
The Creating and Restoring Equal Access to Equivalent Samples Act, a measure aimed at making it easier for generic drug companies to research name brand drugs, was left out of the final budget.
The downgrade to BB from BBB- comes as the drugmaker continues to face challenges such as a competitive generic drug market in the U.S.
Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of generic version of Syprine ®1 (trientine hydrochloride) capsules, 250 mg, in the U.
The Israel-based drug maker reported fourth-quarter numbers that topped analysts' expectations, but its outlook came in below estimates.
While Donald Trump's tweets can shake up pharmaceutical stocks, history suggests that investors have little to fear from the president's drug pricing rhetoric.
The free market is going to take back control of interest rates.
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today reported results for the year and the quarter ended December 31, 2017.
The stock market continues to be under considerable pressure. Here is one thing not to do right now amidst the carnage.
The Dow Jones Industrial Average blew up on Monday, plain and simple. Here is one lesson investors should have learned.
Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for fremanezumab, an anti-calcitonin...
Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced amendments to its USD and JPY term loan and revolving credit facilities, providing the company greater flexibility in its financial leverage ratio...
Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced it has completed the sale of a portfolio of products within its global women's health business across contraception, fertility, menopause and...
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that it will issue a press release on its fourth quarter and full year 2017 financial results on Thursday, February 8, 2018 at 7:00 a.
New York City sues Purdue Pharma, Teva Pharmaceutical, Allergan, Johnson and Johnson, Endo International, McKesson, AmerisourceBergen and Cardinal Health over how opioids have devastated the city and its services.
Gains are being left on the table as firms and investors let their politics or social concerns get the better of them.
Stick to the fundamentals when making investment decisions.
Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced that a Phase III registration study evaluating subcutaneously administered reslizumab (110 mg) in a pre-filled syringe did not meet its primary...
As opioid crisis becomes more deadly, public hearings put the pain killers front and center. But in bitterly divided Washington one meeting is more about chopping Medicaid.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.